跳至主要内容
临床试验/NCT07052721
NCT07052721已完成不适用

A Randomized, Single-Blinded, Sham-Controlled Study Evaluating the Efficacy and Safety of RELAY, a Device Enabling Both Local Anesthetic Delivery and Neuromodulation Following Shoulder or Foot Surgery

University of California, San Diego1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2025年9月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
44
试验地点
1
主要终点
Average daily pain intensity postoperative days 1-7

研究概览

简要总结

Postoperative pain remains undertreated with inadequate analgesic options. Opioids have well-known limitations for both individuals and society; single-injection and continuous peripheral nerve blocks provide intense analgesia but are limited in duration to 24-72 hours; and current neuromodulation options-with a duration measured in weeks and not hours-are prohibitively expensive and require an additional procedure. One possible solution is a device currently under investigation to treat postoperative pain. The RELAY system (Gate Science, Moultonborough, New Hampshire) is comprised of a basic catheter-over-needle device to allow administration of a single-injection of local anesthetic via the needle (or catheter) followed by a perineural local anesthetic infusion via the remaining catheter (when desired). Subsequent to the local anesthetic administration, instead of removing the catheter as with all previous continuous peripheral nerve block equipment, electric current may be delivered via the same catheter and an integrated pulse generator for up to 28 days. This is potentially revolutionary because it would allow an anesthesiologist to deliver (1) a single-injection peripheral nerve block; (2) a continuous peripheral nerve block; and (3) neuromodulation using a single device that can theoretically be placed in the same amount of time required for a single-injection peripheral nerve block. Instead of providing fewer than 24 hours of postoperative analgesia, up to 28 days of pain control could be delivered without disruption of existing practice patterns. The ultimate objective of the proposed investigation is to investigate the post-operative analgesic potential of this investigational device and prepare for a pivotal multicenter clinical trial.

详细描述

For individuals of childbearing potential, a sample of urine will be collected before any study interventions to confirm a non-pregnant state (this is standard procedure for all surgical patients). Participants will have standard external monitors placed and oxygen delivered by facemask or nasal cannula. The peripheral nerve block site(s) will be cleansed with chlorhexidine gluconate and isopropyl alcohol. Intravenous sedation/analgesia with midazolam and/or fentanyl will be titrated for patient comfort as is standard for peripheral nerve block administration. The nerves treated will include the sciatic proximal to the popliteal crease for foot surgery and the brachial plexus for shoulder/clavicle surgery. The target nerve(s) will be visualized with ultrasound using a transverse cross-sectional (short axis) view and a skin wheal of local anesthetic will be raised inferior to the transducer to anesthetize the skin and then the track towards the target.

Participants will be randomly allocated to one of two possible treatments groups: (1) Neuromodulation or (2) Sham [Control].

Randomization will be stratified by anatomic location (shoulder and foot/ankle surgery) in a 1:1 ratio and in blocks of 2. Computer-generated randomization lists will be created by the UC San Diego Investigational Drug Service and participants allocated to the treatment groups in sequential order. Pulse generators are available that are capable of either (1) passing electrical current; or (2) not passing electrical current. Importantly, these 2 modes (active and sham) are indistinguishable in appearance, and therefore investigators, participants, and all clinical staff will be masked to treatment group assignment, with the only exception being the unmasked individuals who insert the RELAY and program the stimulator.

The RELAY system with the integrated needle will be inserted adjacent to the target nerve with an in-plane approach. Dextrose 5% in water (1-20 mL) will be injected via the needle to open a space around the target nerve(s), the catheter advanced, and the needle subsequently withdrawn.

Active treatment group. For participants randomized to active treatment, electrical current will be introduced with increasing intensity using the most proximal and distal electrodes (control provided by the Gate Keeper app from an investigator's phone or tablet). Accurate lead placement will be confirmed with subject reports of comfortable sensations over the surgical site without eliciting muscle contractions. The minimum threshold and maximum comfortable amplitudes will be determined along with the optimal frequency, pulse duration, and anode/cathode. Starting from the lowest possible current the investigators increase the current until the participant states that they feel a "buzzing" sensation (some describe it as a "comfortable massage"). That is the minimal sensed current. The investigators will then continue increasing with the instructions to let them know when it starts to be less comfortable-and to stop us before it hurts. That is the maximum comfortable current. The stimulator will be then set to deliver the minimum threshold amplitude and turned off for surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

盲法说明

Pulse generators are available that are capable of either (1) passing electrical current; or (2) not passing electrical current. Importantly, these 2 modes (active and sham) are indistinguishable in appearance, and therefore investigators, participants, and all clinical staff will be masked to treatment group assignment, with the only exception being the unmasked individuals who insert the RELAY and program the stimulator.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult participants of at least 18 years of age
  • •Undergoing a rotator cuff repair, total shoulder arthroplasty, clavicle fracture ORIF, or foot/ankle surgery anticipated to have moderate-to-severe pain for a week after surgery (e.g., ankle arthroplasty/arthrodesis)
  • •At least a single-injection peripheral nerve block(s) planned
  • •An Android or Apple smartphone able to download the Gate Keeper controller app

排除标准

  • •Chronic opioid or tramadol use (daily within prior 2 weeks and duration > 4 weeks)
  • •Neuro-muscular deficit of the surgical limb
  • •Compromised immune system based on medical history (e.g., immunosuppressive therapies such as chemotherapy, radiation, sepsis, infection), or other conditions that places the subject at increased risk of infection
  • •Implanted spinal cord stimulator, cardiac pacemaker/defibrillator, deep brain stimulator, or other implantable neurostimulator whose stimulus current pathway may overlap
  • •History of bleeding disorder
  • •Antiplatelet or anticoagulation therapies other than aspirin
  • •Allergy to skin-contact materials (occlusive dressings, bandages, tape etc.)
  • •Incarceration
  • •Moderate pain (NRS > 3) in an anatomic location other than the surgical site
  • •Anxiety disorder
  • •History of substance misuse
  • •Inability to communicate with the investigators
  • •Inability to contact the investigators during the treatment period, and vice versa (e.g., lack of telephone access)
  • •Allergy to amide local anesthetics
  • •Morbid obesity (body mass index > 40 kg/m2)

研究组 & 干预措施

Active Neuromodulation

Experimental

RELAY catheter will be inserted under ultrasound guidance followed by a local anesthetic bolus injection. If a patient's surgeon requests a postoperative continuous peripheral nerve block, a ropivacaine 0.2% infusion will be initiated in the recovery room. Within the recovery room, the stimulators will be connected to participants' phones and turned on. The catheters will be removed on postoperative day 7.

干预措施: Experimental Treatment (Device)

Sham Neuromodulation

Sham Comparator

RELAY catheter will be inserted under ultrasound guidance followed by a local anesthetic bolus injection. If a patient's surgeon requests a postoperative continuous peripheral nerve block, a ropivacaine 0.2% infusion will be initiated in the recovery room. Within the recovery room, the stimulators will be connected to participants' phones and turned on, but no current will reach the electrodes or patient's body. The catheters will be removed on postoperative day 7.

干预措施: Sham Comparator (Device)

结局指标

主要结局

Average daily pain intensity postoperative days 1-7

时间窗: Days 1-4 and 7

The median of 4 daily "average" pain intensity scores for Days 1-4 and 7 as measured with the Numeric Rating Scale (0 minimum=best; 10 maximum=worst) collected on Days 2, 3, 4, and 7 for the previous 24 hours each.

次要结局

  • Brief Pain Inventory (interference sub scale)(Postoperative days 3 and 7)
  • Daily "average" pain intensity(Postoperative Days 1-4, 7, 8, and 14)
  • Daily "worst" pain intensity(Postoperative Days 1-4, 7, 8, and 14)
  • Daily oxycodone consumption(Postoperative Days 1-4, 7, 8, and 14)
  • Percentage of group avoiding severe pain (NRS>6)(Postoperative Days 1-14)
  • Percentage of group avoiding opioids(Postoperative Days 1-14)
  • Day of discharge(Postoperative Days 0-14)
  • Blinding assessment(Postoperative Day 7)
  • Cumulative opioid use 1st week(The first 7 days following surgery)
  • Cumulative opioid use 1st week(The first 7 days following surgery)
  • Nightly awakenings due to pain(Collected on postoperative days 1-4, 7, 8, and 14)
  • Daily "worst" pain intensity(Postoperative Days 1-4, 7, 8, and 14)
  • Daily oxycodone consumption(Postoperative Days 1-4, 7, 8, and 14)
  • Day of discharge(Postoperative Days 0-14)
  • Brief Pain Inventory (interference sub scale)(Postoperative days 3 and 7)
  • Daily "average" pain intensity(Postoperative Days 1-4, 7, 8, and 14)
  • Worst/maximum daily pain intensity postoperative days 2-7(Days 1-4 and 7)
  • Awakenings due to pain 1st week, cumulative(Collected on postoperative days 1-7)
  • Percentage of group avoiding severe pain (NRS>6)(Postoperative Days 1-14)
  • Percentage of group avoiding opioids(Postoperative Days 1-14)
  • Blinding assessment(Postoperative Day 7)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Brian M. Ilfeld, MD, MS

Professor of Anesthesiology, In Residence

University of California, San Diego

研究点 (1)

Loading locations...

相似试验